In yesterday’s Wall Street session, Hoth Therapeutics Inc. (NASDAQ:HOTH) shares traded at $6.56, down -15.90% from the previous session.
2 analysts cover Hoth Therapeutics Inc. (NASDAQ:HOTH), according to research data. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $33.00 and a low of $5.00, we find $19.00. Given the previous closing price of $7.80, this indicates a potential upside of 143.59 percent. HOTH stock price is now 45.99% away from the 50-day moving average and -33.36% away from the 200-day moving average. The market capitalization of the company currently stands at $11.68M.
Top 5 Undervalued Stocks To Own In 2023
Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.
Click here to download your Free Research Report…
Sponsored
The stock has received a hold rating from 0 analysts and a buy rating from 2. Brokers who have rated the stock have averaged $19.00 as their price target over the next twelve months.
With the price target of $10, The Benchmark Company recently initiated with Speculative Buy rating for Hoth Therapeutics Inc. (NASDAQ: HOTH).
In other news, Knie Robb, CEO and President bought 10,000 shares of the company’s stock on Sep 19. The stock was bought for $3,900 at an average price of $0.39. Upon completion of the transaction, the CEO and President now directly owns 828,259 shares in the company, valued at $5.43 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Sep 16, CEO and President Knie Robb bought 10,000 shares of the business’s stock. A total of $4,000 was incurred on buying the stock at an average price of $0.40. This leaves the insider owning 818,259 shares of the company worth $5.37 million. A total of 2.90% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in HOTH stock. A new stake in Hoth Therapeutics Inc. shares was purchased by TWO SIGMA SECURITIES, LLC during the first quarter worth $6,000. MILLENNIUM MANAGEMENT LLC invested $4,000 in shares of HOTH during the first quarter. In the first quarter, ROYAL BANK OF CANADA acquired a new stake in Hoth Therapeutics Inc. valued at approximately $2,000. In total, there are 17 active investors with 8.30% ownership of the company’s stock.
On Tuesday morning Hoth Therapeutics Inc. (NASDAQ: HOTH) stock kicked off with the opening price of $7.03. During the past 12 months, Hoth Therapeutics Inc. has had a low of $2.61 and a high of $43.75. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 9.40, and a quick ratio of 9.40. The fifty day moving average price for HOTH is $4.49 and a two-hundred day moving average price translates $9.84 for the stock.
The latest earnings results from Hoth Therapeutics Inc. (NASDAQ: HOTH) was released for Jun, 2022.
Hoth Therapeutics Inc.(HOTH) Company Profile
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-ALZ for the treatment and/or prevention of Alzheimer’s or other neuroinflammatory diseases; HT-003 to treat inflammatory bowel diseases, as well as acne and psoriasis; HT-004 for treatment of asthma and allergies using inhalational administration; HT-006 to treat lung diseases resulting from bacterial infections; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; the University of Maryland; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc.; Zylö Therapeutics, Inc., and the University of Cincinnati. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.
